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ORIGINAL RESEARCH

IV Sotalol Use in Pediatric and Congenital
Heart Patients: A Multicenter Registry Study
Lindsey E. Malloy-Walton , DO, MPH; Nicholas H. Von Bergen , MD; Seshadri Balaji, MBBS, PhD, CEPS-P;
Peter S. Fischbach, MA, MD, CCDS; Jason M. Garnreiter, MD, CEPS-P; S. Yukiko Asaki, MD; Jeffrey P. Moak, MD;
Luis A. Ochoa , MD; Philip M. Chang , MD, CEPS-P; Hoang H. Nguyen , MD; Akash R. Patel, MD, CEPS-P;
Christa Kirk, PharmD, BCCP; Ashley K. Sherman, MA; Jennifer N. Avari Silva , MD, CEPS-P; J. Philip Saul , MD
BACKGROUND: There is limited information regarding the clinical use and effectiveness of IV sotalol in pediatric patients and
patients with congenital heart disease, including those with severe myocardial dysfunction. A multicenter registry study was
designed to evaluate the safety, efficacy, and dosing of IV sotalol.
METHODS AND RESULTS: A total of 85 patients (age 1 day–36 years) received IV sotalol, of whom 45 (53%) had additional congenital cardiac diagnoses and 4 (5%) were greater than 18 years of age. In 79 patients (93%), IV sotalol was used to treat
supraventricular tachycardia and 4 (5%) received it to treat ventricular arrhythmias. Severely decreased cardiac function by
echocardiography was seen before IV sotalol in 7 (9%). The average dose was 1 mg/kg (range 0.5–1.8 mg/kg/dose) over a
median of 60 minutes (range 30–300 minutes). Successful arrhythmia termination occurred in 31 patients (49%, 95% CI [37%–
62%]) with improvement in rhythm control defined as rate reduction permitting overdrive pacing in an additional 18 patients
(30%, 95% CI [19%–41%]). Eleven patients (16%) had significant QTc prolongation to >465 milliseconds after the infusion, with
3 (4%) to >500 milliseconds. There were 2 patients (2%) for whom the infusion was terminated early.
Downloaded from http://ahajournals.org by on November 1, 2022

CONCLUSIONS: IV sotalol was safe and effective for termination or improvement of tachyarrhythmias in 79% of pediatric patients
and patients with congenital heart disease, including those with severely depressed cardiac function. The most common
dose, for both acute and maintenance dosing, was 1 mg/kg over ~60 minutes with rare serious complications.
Key Words: IV sotalol ■ pediatrics ■ supraventricular tachycardia

I

V sotalol, a beta blocker with Class III antiarrhythmic properties, was approved by the US Food and
Drug Administration in 2015. Literature suggests that
IV sotalol can be safely administered in adult patients
achieving rapid, reliable therapeutic results with similar
safety and efficacy to oral sotalol.1–4 Before the availability of IV sotalol, amiodarone was the only IV Class
III antiarrhythmic option for pediatric patients, which
requires ongoing continuous infusion to achieve therapeutic levels as well as close monitoring for cytochrome
P-450 drug-drug interactions. Sotalol given as an intermittent infusion has a more desirable administration

and pharmacokinetic profile in critically ill patients who
may require multiple medications. Additionally, unlike
amiodarone, sotalol is not associated with serious
noncardiac adverse effects such as thyroid dysfunction, blood dyscrasias, neuropathy, or pulmonary fibrosis, which may be of particular importance in pediatric
patients and young adults with congenital heart disease (CHD) who may remain on antiarrhythmic therapy
for many years.
Limited pediatric data support the safety and efficacy of IV sotalol in patients with both supraventricular and ventricular arrhythmias.5–12 The first reports
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CLINICAL PERSPECTIVE
What Is New?

• IV sotalol is safe and effective for termination or
improvement of tachyarrhythmias in pediatric
patients and patients with congenital heart disease, including those with severely depressed
cardiac function.

What Are the Clinical Implications?

• The typical dose used, for both acute and
maintenance dosing, across multiple centers
was 1 mg/kg over ~60 minute with rare acute
sotalol-related complications.

Downloaded from http://ahajournals.org by on November 1, 2022

included patients with structurally normal cardiac
anatomy and normal to mildly depressed cardiac function,5–7 with a few case reports or series of IV sotalol
use in pediatric patients and adults with CHD.8,9,12,13
The most recent studies have concluded that IV sotalol can be used safely and effectively for both acute
and maintenance therapy in young patients with and
without CHD including those with mildly to moderately
depressed cardiac function.10,11 However, there has not
been a large multicenter study looking at IV sotalol use
in a diverse population of pediatric patients and patients with CHD, and there are no studies to date that
have addressed administering IV sotalol to patients
with severe myocardial dysfunction. Thus, the purpose
of this large multicenter registry study was to evaluate
the safety, efficacy, and dosing of racemic IV sotalol
(the Food and Drug Administration approved formulation) in pediatric patients and patients with CHD with
tachyarrhythmias, including those with severely depressed ventricular function.

METHODS
After completing individual site institutional review
board approval and waiver of assent/consent because of the retrospective nature of the study and
standard of care, 14 centers within the United States
completed online de-identified data collection forms
using a REDcap database for pediatric patients
and patients with CHD who received IV sotalol from
August 2017 to May 2020. The data that support the
findings of this study are available from the corresponding author upon reasonable request. The only
inclusion criterion was pediatric patients or patients
with CHD presenting with a tachyarrhythmia who had
a clinical indication for the use of IV sotalol. Pediatric
patients were defined as newborn to age 18 years.
Tachyarrhythmias included reentrant supraventricular

IV Sotalol Use in Pediatric and CHD Patients

tachycardia (SVT) including atrioventricular reciprocating and atrioventricular nodal reentrant tachycardias, atrial tachycardia, atrial flutter/fibrillation,
junctional ectopic tachycardia, hemodynamically
significant frequent atrial or ventricular ectopy, and
ventricular tachycardia. As this was a registry study
on clinical use, there were no specific exclusion criteria. IV sotalol was given either in a stepdown unit
(higher level monitoring than the general floor) or in
the critical care setting with continuous telemetry and
frequent vital sign monitoring at all institutions.
Data collected included patient demographics
and cardiac history. Clinical parameters documented
were vital signs (heart rate and blood pressure) before and after administration of IV sotalol, qualitative
echocardiographic function assessment (defined as
mild, moderate, or severe dysfunction determined by
the reader based on standard quantitative shortening
and ejection fraction measurement criteria), and pre-
and postadministration ECG findings (including QTc
changes and rate/rhythm changes). Providers at individual centers were responsible for echocardiographic
and ECG assessment. Outcome measurements of
efficacy included successful termination (during or
after infusion), time to termination (if specified), and recurrence based on the first dose of IV sotalol given.
The side effect profile, including acute hemodynamic
changes, bradycardia, sinus arrest, proarrhythmic effects, and QTc prolongation with treatment was evaluated. Drug administration data were collected including
the amount of drug administered (calculated in mg/kg
or mg/m2) and the duration of administration (minutes).
For the purposes of analysis, duration of administration
was stratified as very short (≤30 minutes), short (>30
to ≤60 minutes), intermediate (>60–299 minutes), and
long (≥300 minutes).

Statistical Analysis
SAS version 9.4 (SAS Institute Inc., Cary, NC) and R
(R Core Team (2021)) were used for statistical analysis. Descriptive statistics are expressed as mean, SD,
median, and interquartile range depending on the normality of the data. Outlier detection was performed,
defined as values more than 3 or more normalized
absolute deviations from the median as previously
described.14 Paired comparison was performed using
estimation statistics and effect size using the package
dabestr in R. The mean difference and the 95% CI of
the mean difference were calculated by performing
5000 resamples with replacement (bootstrap) from a
single set of paired measurements for each patient.
The effect size was also computed on each of these
resamples.15 Paired comparisons were further stratified by IV sotalol dose.
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RESULTS
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Table 1. Patient Demographic Data

Demographics
There were 85 patients who received IV sotalol (age
range 1 day–36 years), with 53 men (62%). Four patients (5%) were adults with CHD. The median age was
3 months (interquartile range 0.04–3.2 years), median
weight 4.9 kg (interquartile range 3.2–20.1 kg), and the
median height 56 cm (interquartile range 49–95 cm).
Forty-five patients (53%) had congenital cardiac diagnoses. Normal to mildly decreased cardiac function by
qualitative echocardiographic assessment was seen
before IV sotalol in 56 patients (72%), with moderate
dysfunction in 15 (19%) and severely depressed function in 7 (9%) (Table 1).

Indications

Downloaded from http://ahajournals.org by on November 1, 2022

In 79 patients (93%) IV sotalol was used to treat SVT,
2 (2%) for hemodynamically significant premature
atrial contractions, and 4 (5%) received it to treat
ventricular arrhythmias. The SVT group had several
subtypes with the most common being ectopic atrial
tachycardia (n=25, 31%), reentrant SVT (n=24, 30%),
and atrial flutter/fibrillation (n=14, 17%) (see Table 2
for all subtypes). In 49 patients (58%) IV sotalol was
used for acute treatment of a sustained tachyarrhythmia. The remaining patients (n=36, 42%) received
IV sotalol for the following reasons: the need for IV
medication/maintenance dosing (n=12, 14%), systemic organ dysfunction including liver and thyroid
toxicity (n=3, 3.5%), achievement of therapeutic drug
level more efficiently (n=3, 3.5%), risk of drug-drug
interactions (n=1, 1%), and other/not specified (n=17,
20%) (Figure 1).

Administration
The dosing and duration of infusion varied among
centers. The average dose administered was 1 mg/kg
(range 0.5–1.8 mg/kg/dose) over a median of 60 minutes (range 30–
300 minutes) (Figure 2A). Sixteen
patients (21%) had a very short infusion duration of
≤30 minutes, 25 (34%) had a short infusion duration
of >30 to ≤60 minutes, 22 (29%) had an intermediate infusion duration of >60 to 299 minutes, and 12
(16%) had a long infusion duration of 300 minutes
(Figure 2B). Thirty-one patients (37%) received IV sotalol as first-line therapy and 54 (63%) because they
failed other antiarrhythmic medications orally and/
or IV after a washout period at the discretion of the
center (Table 3). Twenty-six patients (31%) received a
single dose of IV sotalol with 16 of these (62%) transitioned to oral sotalol, and 59 (69%) received more
than 1 dose of IV sotalol with 37 of these patients
(63%) transitioned to oral sotalol.

Characteristic

No. (%) or median
(interquartile
range)

Male sex

53 (62)

Age, m

0.3 [0.04–3.20]

Weight, kg

4.9 [3.2–20.10]

Height, cm

56 [49– 95]

Arrythmia diagnosis
Supraventricular tachycardia

79 (93)

Hemodynamically significant premature atrial
contractions

2 (2)

Ventricular tachycardia/fibrillation

4 (5)

Cardiac function (qualitative)
Normal-mildly decreased

56 (72)

Moderately decreased

15 (19)

Severely decreased

7 (9)

Congenital heart disease

45 (53)

Ebstein’s anomaly

3

Atrioventricular canal defect

4

Atrial septal defect

2

VSD

3

Coarctation of the aorta

1

Cardiomyopathy ( including dilated,
restrictive, and hypertrophic)

8

Single ventricle anatomy (double inlet left
ventricle, double outlet right ventricle,
hypoplastic left heart syndrome, heterotaxia
syndrome)

11

D-Transposition of the great arteries

2

L-Transposition of the great arteries

1

Aortic stenosis

3

Tetralogy of Fallot, pulmonary stenosis

2

Pulmonary atresia, VSD-MAPCA

2

Mitral stenosis, congenital

2

Cardiac, other

1

Adults with congenital heart disease

4 (5)

Congenital mitral valve stenosis

1

Ebstein’s anomaly

1

Congenital aortic valve stenosis

1

Pulmonary atresia, VSD-MAPCA

1

MAPCA indicates major aortopulmonary collateral arteries; and VSD,
ventricular septal defect.

Postinfusion Outcomes
After a single dose of IV sotalol, successful arrhythmia termination occurred in 31 patients (49%, 95% CI
[37%–62%]), and an improvement in rhythm control
occurred, defined as rate reduction permitting overdrive pacing based on patient age and hemodynamic
tolerance in an additional 18 patients (30%, 95% CI
[19%–41%]). Patients with reentrant SVT and ectopic
atrial tachycardia had high conversion rates (Table 2).
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Table 2. Arrythmia Type and Conversion Rate
Type of SVT

No.
(%)

Sotalol
conversion (%)

Ectopic atrial tachycardia

25 (31)

17/22 (77)

Reentrant SVT (atrioventricular reentry
tachycardia/atrioventricular nodal reentry
tachycardia)

24 (30)

14/15 (93)

Atrial flutter/fibrillation

14 (17)

6/12 (50)

Permanent junctional reciprocating
tachycardia

3 (4)

1/2 (50)

Junctional ectopic tachycardia

2 (2)

2/2 (100)

Multifocal atrial tachycardia

2 (2)

2/2 (100)

Premature atrial contractions
(hemodynamically significant)/atrial ectopy

2 (2)

1/2 (50)

Iintra-atrial reentrant tachycardia

1 (2)

N/A

Not specified

8 (10)

5/6 (83)

SVT indicates supraventricular tachycardia.

Patients who were not in an active arrythmia at the time
of administration were not included. The median time to
arrhythmia termination was 44 minutes after IV sotalol
initiation when specified (29 patients). Recurrences occurred in 25 patients (35%, 95% CI [24%–46%]) with
time to recurrence ranging from 30 minutes up to
2 weeks, with a median of 10 hours.
Downloaded from http://ahajournals.org by on November 1, 2022

Adverse Events
Although many of the vital signs remained stable after
IV sotalol infusion, there was, as expected, a significant
decrease in mean heart rate of 29 beats per minute
(−29 bpm) (95% CI [−39 to −19.5]) from baseline to end of
treatment without severe hemodynamic compromising
bradycardia reported. The mean initial heart rate before
infusion was 151 bpm (N=77), with a mean final heart
rate after infusion of 122 bpm. The mean difference
in systolic blood pressure was minimal at −1 mm Hg

(95% CI [−4.09 to 2.15]). The mean systolic blood pressure at baseline was 82 mm Hg (N=67) and the mean
systolic blood pressure post infusion was 81 mm Hg.
Finally, the mean difference in post-
infusion QTc
(452 milliseconds, N=65) and baseline QTc (439) was
13 milliseconds (95% CI [0.85–23.2]). When including
only patients with recorded IV sotalol dose, there was
a significant decrease in heart rate post infusion (N=74;
mean difference −30.5 bpm; 95% CI [−43.9 to −17.3]),
no significant decrease in systolic blood pressure post
infusion (N=64; mean difference was −0.516 mm Hg;
95% CI [−6.3 to 5.81]), and an increase in mean QTc
post-infusion (N=63; mean difference of 12.7 milliseconds; 95% CI [0.397–24]) (Figure 3). Eleven patients
(16%) had significant QTc prolongation to >465 milliseconds after initial infusion. To account for baseline
interventricular conduction delay/bundle-branch block
there had to be a >10 millisecond increase from the
baseline QTC measurement. There was a marked QTc
increase in 3 patients (4%) to >500 milliseconds with
a dosing range of 30 to 300 minutes (Figure 4). Some
patients experienced a substantial decrease in QTc
after sotalol infusion likely confounded by the accuracy
of measurement during tachycardia. Rare acute severe
sotalol-related complications were seen in 2 patients
requiring early infusion termination: second-
degree
heart block in a 1-month-old with single ventricle anatomy, common atrium, double outlet right ventricle, and
torsades de pointes in a 19-year-old with ventricular
tachycardia in the setting of congenital mitral valve stenosis status post valve replacement with severe mitral
regurgitation.

DISCUSSION
This is the first large multicenter study to evaluate the
efficacy, dosing, and safety of IV sotalol in pediatric

Figure 1. Indications for use of IV sotalol.
This graph depicts the primary indications for use of IV sotalol, including acute arrhythmia treatment
(58%), need for IV antiarrhythmic/maintenance dosing (14%), systemic organ dysfunction (3.5%), to
achieve therapeutic drug levels (3.5%), owing to drug-drug-interaction risk (1%) and other (20%).
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Figure 2. IV sotalol infusion duration.
A, Time duration for IV sotalol drug infusion. This box-whisker plot shows the median drug infusion duration of 60 minutes (range
30–300 minutes) for all-comers. B, Percentage of patients who received IV sotalol infusions by duration. Drug duration infusions were
categorized as very short (≤30 minutes), short (>30 to ≤60 minutes), intermediate (>60 to 299 minutes), and long (≥300 minutes). A total
of 16 patients (21%) had a very short infusion duration, 25 (34%) had short infusion, 22 (29%) had an intermediate infusion duration,
and 12 (16%) had a long infusion duration.

Downloaded from http://ahajournals.org by on November 1, 2022

patients and patients with CHD with tachyarrhythmias,
including those with severely depressed ventricular
function. Although most patients received IV sotalol
for acute treatment of tachyarrhythmias, clinicians also
chose IV sotalol because of clinical factors such as
multiorgan system dysfunction as well as drug-specific
preferences including need for intermittent IV medication, avoidance of drug-drug interactions, and desire to
achieve therapeutic effect more quickly.
Novel to this study is the use of IV sotalol in 7 patients with severely depressed cardiac function. This
was a small subgroup of the overall cohort; however,
no significant adverse events were recorded in these
patients. Similar to previous hemodynamic clinical
studies of IV and oral sotalol16 our study demonstrates
that there were no deleterious hemodynamic sequelae
attributable to negative inotropic effects, even in those
with severely depressed ventricular function. There
was not a statistically significant change in blood pressure before and after infusion. This is unlike the data
recently reported with IV amiodarone administration
Table 3. First-Line Antiarrhythmic Medication Used
Antiarrhythmic medication

No. of patients (%)

IV sotalol

31 (37%)

Oral beta blockers

16 (19%)

IV beta blockers

18 (21%)

Flecainide

1 (1%)

Digoxin oral/IV

7 (8%)

Verapamil IV

1 (1%)

Procainamide IV

3 (4%)

Amiodarone oral/IV

6 (7%)

Lidocaine IV

2 (2%)

and the risk of developing cardiovascular collapse in
a significant subset of children, especially in young infants, patients with hemodynamic compromise, and
patients receiving rapid amiodarone bolus administration.17 Although this study did not specifically look
at IV amiodarone versus IV sotalol, it suggests a need
to reconsider the perceived advantage and safety of
amiodarone and consider an expanded role of IV sotalol in pediatric arrhythmia management.
The preferred method of initiating IV sotalol is unclear
at present. Valdes et al. used 1 mg/kg over an hour for
their acute arrhythmia termination group and 80% to
90% of the patient’s prior daily oral maintenance dosage of sotalol divided every 8 to 12 hours over 5 hours
in those receiving IV maintenance therapy.10 Perry et al.
reported a standardized target dose of 30 to 40 mg/
m2 over 15 minutes for the acute arrythmia termination
group and maintenance dosing based on a 1:1 ratio
of the recommended oral dose with intermittent doses
every 8 to 12 hours to reach a daily dose of 50 mg/m2
per day or 3 mg/kg per day infused over 2 hours.11 Our
data show, for both acute and maintenance dosing,
that the mean administration of IV sotalol across multiple centers was 1 mg/kg over a median of 60 minutes. Some centers in this study used an IV sotalol
infusion duration ≤30 minutes without complications
consistent with published experience from Perry et al.11
The median time to arrhythmia termination was longer (44 minutes) when compared with previous studies
(time to termination 33 minutes, 14 minutes),10,12 likely
reflecting variable dosing regimens among participating centers. The most common arrythmia substrates
were ectopic atrial tachycardia (31%), reentrant SVT
(30%), and atrial flutter/fibrillation (17%). Patients with
ectopic atrial tachycardia comprised a larger portion of
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Figure 3. Baseline and postinfusion measurements (heart rate, systolic blood pressure, corrected QTc).
The slope graphs show the baseline and postinfusion values categorized by the IV sotalol dose received. The panel on the left
contains paired measurements connected by lines (slopes) showing the direction of change between baseline and post infusion. The
panel on the right shows the mean difference (black dot, delta) along with the bootstrap sampling distribution (shaded bell curve),
and the 95% CI (black bar extending on both sides of the dot). There was a significant decrease in HR post infusion. There was an
insignificant decrease in SBP. There was a slightly significant increase in QTc interval post infusion. HR indicates heart rate; and SBP,
systolic blood pressure.

recipients in our study compared with those of Valdes
et al. (17%) and a smaller portion compared with Li et
al. (43%). Of note, since the start of this study (March

2020), the Food and Drug Administration indications
have expanded to include a 1-
day outpatient infusion approach for atrial fibrillation management that

Downloaded from http://ahajournals.org by on November 1, 2022

Total patients
N=85

Not reported
N=15 (18%)

No QTc prolongation
N=56 (66%)

QTc prolongation
N= 14 (16%)

>465 ms and
>10 ms from baseline
N= 11 (13%)

>500 ms
N=3 (3%)

492--> 575 ms- given over 30 minutes
452--> 546 ms- given over 60 minutes
486--> 514 ms- given over 300 minutes
Figure 4. Impact of IV sotalol on QTc measurements.
QTc measurements were assessed post IV sotalol infusion. There was no QTc prolongation noted
in 56 (66%) patients. QTc prolongation was noted in 14 (16%) patients, with extreme prolongation of
>500 milliseconds noted in 3 (3%) patients.
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replaces the standard multiday oral load in adults.
These new data could potentially lead to the increased
use of IV sotalol, especially in patients with CHD who
are at increased risk for atrial arrhythmias.
As with previous studies, our multicenter experience with IV sotalol demonstrates it to be efficacious in the termination, reduction, and/or rate
control across a variety of tachyarrhythmias.10,11 In
some cases, IV sotalol was given as first-line therapy; however, many patients were given IV sotalol
following failure with other antiarrhythmic medications. Giving sotalol after other agents could have
positive or negative effects on rhythm management.
There are known limitations and adverse events
specifically with pediatric IV amiodarone administration. Chang et al. noted if partial and full success
were combined, procainamide was successful in
71% of cases compared with 34% for amiodarone
(P=0.046). If partial success is considered a treatment failure, procainamide was successful in 50%
compared with 15% for amiodarone (P=0.029).18
Other IV options such as procainamide, digoxin,
esmolol, and lidocaine have analogous limitations
to amiodarone and to each other based on dosing,
administration times, or efficacy for conversion of
acute arrhythmias.11 Given the variety of arrhythmias
and the lack of comparison to alternative therapy,
additional studies are needed to compare IV sotalol
with other antiarrhythmic medications in specific arrhythmia substrates.
With the known risk of QTc prolongation and potential for proarrhythmic effects, an understanding of
the safety of IV sotalol is vital. In our experience, IV
sotalol appeared relatively safe for the treatment of
atrial, ventricular, and junctional tachyarrhythmias in
a heterogeneous population spanning a broad age
range. This included patients that had a baseline
QTc >460 milliseconds given the nature of this patient population (CHD with intraventricular conduction
delay/bundle-branch block). The 2% rate of serious
adverse events in this patient cohort was lower than
previously described by Valdes et al. (4%) but higher
than reported by Perry et al. (0%).10,12 The 2 patients
who required early termination had significant issues
including bradycardia with second-
degree heart
block in the setting of other concomitant antiarrhythmic medications (amiodarone, procainamide, and esmolol), and torsades de pointes in the setting of QTc
prolongation (up to 514 milliseconds) after 2 infusions
(12 hours apart) of 1.4 mg/kg per dose each given
over 300 minutes. Our study supports the prior literature that although rare, because of hemodynamic
and proarrhythmic risks, IV sotalol should always be
administered with close monitoring including heart
rate, blood pressure, rhythm evaluation, and ECG
assessment.

IV Sotalol Use in Pediatric and CHD Patients

Limitations
Study limitations are related primarily to the challenges associated with multicenter data collection
and interpretation. Data entry was rarely incomplete from participating centers, which may limit
the results and conclusions. The maximum percentage of missing data in any single data field
was 12% (noted for baseline systolic and diastolic
BP with 2 reported as means and not used in calculations). All efforts were made to obtain missing
data in the data collection set. Echocardiographic
data were based on qualitative reader assessment,
which has an element of subjectivity. Data review
and validation were limited to the registry database because there was no access to individual
centers’ medical records. Postinfusion outcomes
were based on a single IV sotalol dose. More studies are needed to look at outcomes after several
IV sotalol doses. In addition, the adult CHD data
are limited in both number and type of underlying
heart disease. The number of patients with severe
ventricular dysfunction is also low and this means
no major conclusions can be drawn about safety
in this population of patients. Further multicenter
studies could be useful to look specifically at these
patient populations.

CONCLUSIONS
Based on the findings of this large multicenter registry, IV sotalol can be used safely to treat tachyarrhythmias in pediatric patients and patients with CHD.
There were no significant adverse events noted in
those with severely depressed ventricular function.
The typical dose used, for both acute and maintenance dosing, across multiple centers was 1 mg/kg
over ~60 minute with rare acute sotalol-related complications. Further studies are needed in pediatric
patients, as well as adults with CHD, to compare IV
sotalol with other antiarrhythmic medications for specific arrhythmia substrates.
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